Search: L773:1941 837X
> (2010-2014) >
Willingness to pay ...
Willingness to pay for diabetes drug therapy in type 2 diabetes patients : based on LEAD clinical programme results
-
- Jendle, Johan, 1963- (author)
- Örebro universitet,Institutionen för hälsovetenskap och medicin,Endocrine and Diabetes Centre, Karlstad Hospital, Karlstad, Sweden; Örebro University Hospital, Örebro, Sweden
-
- Torffvit, O. (author)
- Center for Primary Health Care Research, University Hospital of Skåne, Lund, Sweden
-
- Ridderstråle, M. (author)
- Department of Endocrinology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Malmö, Sweden
-
show more...
-
- Ericsson, Å. (author)
- Novo Nordisk Scandinavia, Malmö, Sweden
-
- Nilsen, B. (author)
- Novo Nordisk Scandinavia, Malmö, Sweden
-
- Bøgelund, M. (author)
- Incentive Partners, Holte, Denmark
-
show less...
-
(creator_code:org_t)
- 2012-08
- 2012
- English.
-
In: Journal of Medical Economics. - Oxfordshire, United Kingdom : Taylor & Francis. - 1369-6998 .- 1941-837X. ; 15:Suppl 2, s. 1-5
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- Objective: The purpose of this study was to investigate the preferences of people with diabetes for liraglutide vs other glucose lowering drugs, based on outcomes of clinical trials.Methods: Willingness to pay (WTP) for diabetes drug treatment was assessed by combining results from a recent WTP study with analysis of results from the Liraglutide Effect and Action in Diabetes (LEAD) programme. The LEAD programme included six randomised clinical trials with 3967 participants analysing efficacy and safety of liraglutide 1.2 mg (LEAD 1-6 trials), rosiglitazone (LEAD 1 trial), glimepiride (LEAD 2-3 trials), insulin glargine (LEAD 5 trial), and exenatide (LEAD 6 trial). The WTP survey used discrete choice experimental (DCE) methodology to evaluate the convenience and clinical effects of glucose lowering treatments.Results: People with type 2 diabetes were prepared to pay an extra €2.64/day for liraglutide compared with rosiglitazone, an extra €1.94/day compared with glimepiride, an extra €3.36/day compared with insulin glargine, and an extra €0.81/day compared with exenatide. Weight loss was the largest component of WTP for liraglutide compared with rosiglitazone, glimepiride, and insulin glargine. Differences in the administration of the two drugs was the largest component of WTP for liraglutide (once daily anytime) compared with exenatide (twice daily with meals). A limitation of the study was that it was based on six clinical trials where liraglutide was the test drug, but each trial had a different comparator, therefore the clinical effects of liraglutide were much better documented than the comparators.Conclusions: WTP analyses of the clinical results from the LEAD programme suggested that participants with type 2 diabetes were willing to pay appreciably more for liraglutide than other glucose lowering treatments. This was driven by the relative advantage of weight loss compared with rosiglitazone, glimepiride, and insulin glargine, and administration frequency compared with exenatide.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- Medicin
- Medicine
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database